Moderna, Inc. (FRA:0QF)

Germany flag Germany · Delayed Price · Currency is EUR
20.58
+0.01 (0.02%)
Nov 7, 2025, 5:58 PM CET
0.02%
Market Cap8.37B
Revenue (ttm)1.90B
Net Income (ttm)-2.66B
Shares Outn/a
EPS (ttm)-6.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume283
Average Volume56,366
Open20.89
Previous Close20.58
Day's Range20.25 - 21.21
52-Week Range19.89 - 54.20
Betan/a
RSI45.06
Earnings DateNov 6, 2025

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5,800
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0QF
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD Financial Statements

News

Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street esti...

4 days ago - Nasdaq

Moderna (MRNA) Reports Q3 Revenue and Strategic Developments

Moderna (MRNA) Reports Q3 Revenue and Strategic Developments

4 days ago - GuruFocus

Moderna, Inc. (MRNA) Q3 2025 Earnings Call Transcript

Moderna, Inc. (MRNA) Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsLavina Talukdar - Senior VP & Head of Investor...

5 days ago - Seeking Alpha

Moderna Inc (MRNA) Q3 2025 Earnings Call Highlights: Strategic Cost Reductions Amid Revenue ...

Moderna Inc (MRNA) Q3 2025 Earnings Call Highlights: Strategic Cost Reductions Amid Revenue Challenges

5 days ago - GuruFocus

Q3 2025 Moderna Inc Earnings Call Transcript

Q3 2025 Moderna Inc Earnings Call Transcript

5 days ago - GuruFocus

mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast

Moderna Inc. (NASDAQ: MRNA) reported a third-quarter loss of 51 cents, beating the expected loss of $2.02 , a turnaround from an income of 3 cents a year ago. MRNA stock is racing ahead of the pack. ...

5 days ago - Benzinga

mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast

Moderna Inc. (NASDAQ:MRNA) reported a third-quarter loss of 51 cents, beating the expected loss of $2.02, a turnaround from an income of 3 cents a year ago.

5 days ago - Benzinga

Moderna Q3 2025 Earnings Call Transcript

Moderna, Inc (NASDAQ: MRNA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. MRNA is building positive mome...

5 days ago - Benzinga

Investor Outlook: Moderna posts stronger Q3 as cost-cutting cushions weaker COVID vaccine sales

Moderna beats Q3 forecasts as cost-cutting offsets weaker COVID vaccine sales and new mRNA cancer trials advance.

5 days ago - BNN Bloomberg

Moderna begins trails in cancer treatment vaccine

Geoff Meacham, managing director, biotech & pharma equity research at Citi, joins BNN Bloomberg to discuss Moderna's Q3 earnings.

5 days ago - BNN Bloomberg

Moderna Posts Loss In Q3

(RTTNews) - Moderna (MRNA) posted a third-quarter net loss of $200 million compared to net income of $13 million, last year. Loss per share was $0.51 compared to profit of $0.03. Analysts on average e...

5 days ago - Nasdaq

Moderna Surges; Covid Vaccine Sales Decline, But Top Expectations

Moderna stock surged Thursday. Though third-quarter vaccine sales declined, they came in above expectations.

5 days ago - Investor's Business Daily

Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates

Moderna (MRNA) delivered earnings and revenue surprises of +76.28% and +18.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

5 days ago - Nasdaq

Moderna (MRNA) Surpasses Earnings and Revenue Expectations

Moderna (MRNA) Surpasses Earnings and Revenue Expectations

5 days ago - GuruFocus

Moderna (MRNA) Surpasses Q3 Revenue Forecasts Despite Decline

Moderna (MRNA) Surpasses Q3 Revenue Forecasts Despite Decline

5 days ago - GuruFocus

Moderna (MRNA) Projects Lower Cost of Sales for 2025

Moderna (MRNA) Projects Lower Cost of Sales for 2025

5 days ago - GuruFocus

Moderna (MRNA) Reports Strong Q3 Revenue Boosted by COVID Vaccine Sales

Moderna (MRNA) Reports Strong Q3 Revenue Boosted by COVID Vaccine Sales

5 days ago - GuruFocus

Moderna Inc (MRNA) Q3 2025 Earnings: EPS of $(0. ...

Moderna Inc (MRNA) Q3 2025 Earnings: EPS of $(0.51) Beats Estimate, Revenue Surpasses Expectations at $1.0 Billion

5 days ago - GuruFocus

Moderna trims top end of full-year forecast on weak COVID vaccine sales

Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of its COVID-19 vaccine in the U.S. as Americans struggled to access the shots.

5 days ago - Reuters